Navigation Links
Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Date:8/30/2007

GRONINGEN, Netherlands, Aug. 31 /PRNewswire-FirstCall/ -- Oncology focused pharmaceutical development company Kiadis Pharma announced today that it has successfully completed a Phase II clinical trial evaluating its product Reviroc(TM). Reviroc is used to eliminate cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. Data from the clinical study revealed improved overall survival of Reviroc-treated patients. The successful completion of the clinical trial allows Kiadis Pharma to prepare for a Phase III clinical study.

Manja Bouman, CEO, Kiadis Pharma, comments: "We are obviously very pleased with the completion of this Phase II trial of Reviroc. It brings treatment with our product a step closer to patients with end stage blood cancer. Reviroc shares its development platform with two other Kiadis Pharma products: ATIR and Rhitol. The results of this trial therefore mark an important milestone in the development of our entire clinical product pipeline."

In the non-randomized open label study 25 patients, each of whom had reached end stage Non-Hodgkin's lymphoma, were treated in multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that Reviroc does not negatively impact the graft itself.

The Reviroc clinical trial data was evaluated against a historical patient control group from the Center for International Blood and Marrow Transplant Research (CIBMTR). The results for Reviroc-treated patients were compared with results from the CIBMTR database for patients who had received an autologous transplant without Reviroc. The outcome of this comparison shows that the Reviroc-treated patient group had an 80% chance of survival at 3 years post transplantation, while the CIBMTR control group had a 55% chance of
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... BRIC Gynecological Devices Market Outlook to ... new report, "BRIC Gynecological Devices Market Outlook to ... Gynecological Devices market. The report provides value, in ... average prices (in US dollars) within market segments ... and Mechanical Sterilization Devices (Tubal Clips and Rings)), ...
(Date:9/17/2014)... Sept. 17, 2014 The ambulance ... last decade due to the recession, an ... technological advancements. This BCC Research report analyzes ... of the ambulance and emergency medical services ... and hemorrhage control devices, equipment used for ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 Pomerantz ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... BioPharma and certain of its officers and/or directors have ... Act of 1934.  On September 17, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
(Date:9/17/2014)... 17, 2014 People who struggle to distinguish ... to http://www.perwickstrom.com and get the answer by reading ... point out, is that a business plan and a business ... together, commented Per Wickstrom. “The way I view it is ... business strategy which is part two.” , According to ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Social networking sites can help ... For people who are obese, sites like Twitter and ... support from doctors as well as peers, researchers found. ... methods is that it offers the potential to be ... when compared to traditional approaches," the study,s lead author, ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:North Central Surgical Center Receives Several Accolades 2Health News:New OptiPact™ Technology Introduced by Catalent 2
... ... virtual reality device, the GaitAid, can help stroke patients learn to walk better. , ... Haifa, Israel (PRWEB) February 22, 2010 -- There are ... one of the leading causes of adult disability in the U.S. and Europe., , , , ...
... new survey has found that African-Americans are more likely ... lung cancer, as well as being more reluctant to ... according to researchers from Dana-Farber Cancer Institute and their ... the puzzling racial disparities in lung cancer treatment outcomes ...
... outlets for buying booze increases, so does neighborhood violence, ... The more bars, restaurants and other alcohol sales sites ... say researchers who studied crime statistics and alcohol licensing ... found an association between high assault rates and stores ...
... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
... types of minimally invasive surgery to repair kidney blockages ... found that robot-assisted surgery was faster and resulted in ... in the Canadian Journal of Urology , Ashok ... Baptist Medical Center, compared laparoscopic and robot-assisted surgery for ...
... 20. "Nanotechnology could aid the future of development of the ... the academy of sciences for the developing world, and president ... at a panel session, "Re-emergence of Science, Technology and Education ... AAAS,s annual meeting in San Diego. "The Arab ...
Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:African-Americans' attitudes about lung cancer may hinder prevention 2Health News:More Bars Equals More Assaults, Study Finds 2Health News:Comparison shows robot-assisted option offers advantages for kidney surgery 2Health News:Nanotechnology could help Arab region 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: